Joana Carvalho

List of Publications by Year in descending order

26 papers	5,965 citations	516710 16 h-index	642732 23 g-index
29 all docs	29 docs citations	29 times ranked	11326 citing authors

#	Article	IF	Citations
1	Mutant KRAS-Associated Proteome Is Mainly Controlled by Exogenous Factors. Cells, 2022, 11, 1988.	4.1	2
2	Cross-cultural adaptation and validation of the Swallowing Disturbance Questionnaire and the Sialorrhea Clinical Scale in Portuguese patients with Parkinsonâ€™s disease. Logopedics Phoniatrics Vocology, 2021, 46, 163-170.	1.0	5
3	Speech intelligibility of Parkinsonâ€™s disease patients evaluated by different groups of healthcare professionals and naÃ¯ve listeners. Logopedics Phoniatrics Vocology, 2021, 46, 141-147.	1.0	5
4	Integrated Analysis of Structural Variation and RNA Expression of FGFR2 and Its Splicing Modulator ESRP1 Highlight the ESRP1amp-FGFR2norm-FGFR2-IIIchigh Axis in Diffuse Gastric Cancer. Cancers, 2020, 12, 70.	3.7	13
5	Gastric Cancer Extracellular Vesicles Tune the Migration and Invasion of Epithelial and Mesenchymal Cells in a Histotype-Dependent Manner. International Journal of Molecular Sciences, 2019, 20, 2608.	4.1	8
6	3D Cellular Architecture Affects MicroRNA and Protein Cargo of Extracellular Vesicles. Advanced Science, 2019, 6, 1800948.	11.2	91
7	CDH1 somatic alterations in Mexican patients with diffuse and mixed sporadic gastric cancer. BMC Cancer, 2019, 19, 69.	2.6	12
8	Codon misreading tRNAs promote tumor growth in mice. RNA Biology, 2018, 15, 1-14.	3.1	30
9	Targeting miR-9 in gastric cancer cells using locked nucleic acid oligonucleotides. BMC Molecular Biology, 2018, 19, 6.	3.0	16
10	The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors. International Journal of Molecular Sciences, 2018, 19, 2079.	4.1	26
11	Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. ACS Nano, 2016, 10, 3886-3899.	14.6	397
12	Biological properties of extracellular vesicles and their physiological functions. Journal of Extracellular Vesicles, 2015, 4, 27066.	12.2	3,973
13	Hereditary Diffuse Gastric Cancer Syndrome. JAMA Oncology, 2015, 1, 23.	7.1	540
14	Extracellular Vesicles Ã¢â‚¬â€œ Powerful Markers of Cancer EVolution. Frontiers in Immunology, 2014, 5, 685.	4.8	19
15	Therapeutic targets associated to E-cadherin dysfunction in gastric cancer. Expert Opinion on Therapeutic Targets, 2013, 17, 1187-1201.	3.4	21
16	Somatic Mutations and Deletions of the E-Cadherin Gene Predict Poor Survival of Patients With Gastric Cancer. Journal of Clinical Oncology, 2013, 31, 868-875.	1.6	145
17	E-Cadherin Germline Mutations. , 2013, , 35-49.		2
18	Non-CDH1-Associated Familial Gastric Cancer and Epigenetics Factors. , 2013, , 111-125.		0

#	Article	IF	Citations
19	Alternative Mechanisms to Germline CDH1 Mutations in Hereditary Diffuse Gastric Cancer. , 2013, , 87-96.		0
20	Transcription initiation arising from E-cadherin/CDH1 intron2: a novel protein isoform that increases gastric cancer cell invasion and angiogenesisâ€. Human Molecular Genetics, 2012, 21, 4253-4269.	2.9	16
21	Eâ€cadherin dysfunction in gastric cancer â€•Cellular consequences, clinical applications and open questions. FEBS Letters, 2012, 586, 2981-2989.	2.8	74
22	Lack of microRNAâ€101 causes Eâ€cadherin functional deregulation through EZH2 upâ€regulation in intestinal gastric cancer. Journal of Pathology, 2012, 228, 31-44.	4.5	125
23	Epithelial E- and P-cadherins: Role and clinical significance in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 297-311.	7.4	137
24	1Alpha,25-dihydroxyvitamin D3 induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation. Anticancer Research, 2012, 32, 249-57.	1.1	63
25	Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Human Molecular Genetics, 2010, 19, 943-952.	2.9	100
26	Quantification of Epigenetic and Genetic 2nd Hits in CDH1 During Hereditary Diffuse Gastric Cancer Syndrome Progression. Gastroenterology, 2009, 136, 2137-2148.	1.3	142